Key Takeaways
- Record quarter, peak realizations: Revenue surged 93% YoY in Q4, with caustic soda ECU realization hitting ~₹49,300 per ton, driving EBITDA margin to an all-time high of 35%.
- Guidance implies a step-up, not a peak: Management guided FY23 value growth of 50% and volume growth of 20%, betting that new high-value derivatives (ECH, CPVC) will more than compensate if caustic soda realizations moderate.
- Integration is the moat: The fully integrated complex, where chlorine and hydrogen feed directly into downstream derivatives, is credited for margin resilience and is the logic behind the current expansion cycle.
- Debt has peaked: Gross debt hit ₹965 Cr, but with no further borrowing planned for the chlorotoluene project and ~₹140 Cr in annual repayments, the debt-to-EBITDA ratio is guided to stay below 2%.
- What to watch next quarter: The ECH plant commissioning (targeted by June 2022), the trajectory of ECU realizations from the ~₹50,000 level, and any signal on whether power costs have truly peaked.
The Realization Super-Cycle & Margin Peak
- ECU realization surge: Caustic soda ECU realization rose 74% YoY to ₹37,062 for FY22, with Q4 spiking to ~₹49,000, driven by strong demand, supply tightness from the European energy crisis, US force majeure, and high logistical costs that turned India into a net exporter.
- Margin expansion: EBITDA nearly doubled to ₹509 Cr, with margin expanding to 33% for the full year and hitting 35% in Q4, aided by the ability to pass through raw material and coal cost increases to customers amid high product demand.
- Power cost headwind absorbed: Average power cost was ₹7.67/unit for FY22 and ₹9.15/unit in Q4, but the EBITDA spread per kg remained broadly stable as higher coal costs were passed through to caustic soda realizations; management feels the power cost is at its peak but cannot predict the direction from here.
- Domestic focus by choice: Exports were only 5% of sales in FY22 because domestic realizations were better; the strategy is flexible and realization-based, not a fixed ratio, though Gujarat's coastal location makes exporting more volume easy if required.
- Realization outlook: Management expects ECU realization to remain in the ₹49,000–₹50,000 range in coming quarters and believes there is no possibility of a return to the low levels of FY2021 or Q1 of FY2022, though a correction is possible if energy costs decline.
Maulik Patel: "I believe that in coming times irrespective of anything there is no possibility to reach back to original level of FY2021 or the first quarter of FY2022 so there is a possibility it might go down little bit, but I do not think so it will come back to original level of FY2021 or Q1 of FY2022."
The Derivative-Led Growth Pivot
- Three projects, one thesis: ECH, CPVC, and a 110,000-ton caustic soda expansion are set to commission one-by-one in the next 3–4 months, with all three expected to run for a full year in FY24; the caustic soda expansion is explicitly for internal consumption of chlorine and hydrogen into these derivatives, not for merchant sale.
- ECH demand-supply tightness: ECH is in peak global demand from infrastructure, automobile, windmill, epoxy resin, pharma, and water treatment; Indian demand is growing double-digit from 75,000–80,000 KTPA toward 110,000 KTPA, and management expects supply tightness to persist for the next 1–2 years.
- CPVC as a structural play: CPVC targets hot-water pipe applications for households, adding a domestic consumption story alongside ECH's industrial demand drivers.
- Asset turnover uplift: ECH and CPVC carry higher asset turnover ratios than legacy products, which management argues will lift absolute EBITDA even if legacy realizations normalize.
- Revenue bridge to ₹5,000 Cr: At current conditions, ECH and CPVC on a full-year basis can reach close to ₹3,000 Cr; the chlorotoluene value chain (capex ~₹180 Cr, spending split across FY23 and FY24) will add around ₹3,500 Cr eventually across two phases, forming the path to the ₹5,000 Cr FY27 target.
- Commissioning cadence: ECH trial runs were planned from May 15, 2022, with full commissioning by end of May or early June; CPVC is expected early Q2 FY23; both typically take three months to ramp from ~50% to optimum utilization, so FY23 gets partial benefit and FY24 gets the full year.
Maulik Patel: "Currently the ECH is in peak demand due to the infrastructure projects are going on all over the world and the demand has picked up after the COVID situation... we continue to believe that it will remain the same for next I think next one or two years' time."
FY23 Guidance: Volume, Value & the Mix Shift
- Headline guidance: 20–22% volume growth and 50% value growth in FY23, implying revenue of approximately ₹2,250 Cr, which beats the earlier ₹2,000 Cr target one year ahead of schedule.
- The mix-shift logic: The 50% value growth guidance is built on the assumption that ECH and CPVC are high-value products; even if caustic soda realizations are at a peak, the new derivative mix provides visible confidence in hitting the number.
- Volume drivers: The ~20% volume growth is expected to come from the three new projects (ECH, CPVC, caustic soda expansion), with ECH and CPVC as the major contributors in both FY23 and FY24.
- Long-term margin guardrail: Management guided long-term EBITDA margins in the range of 28% ±2% (26–30%), with the conservative end at 26% and the upside at ~30% if prices move as anticipated; absolute EBITDA is expected to improve ROCE.
- Caustic soda demand underpinning: Demand is growing year-by-year, with India requiring one sizable caustic soda plant commissioned every year to meet growth from infrastructure, renewable energy, pharmaceuticals, agrochemicals, and PLI schemes; paper and textile sectors, weak in FY22, have picked up in the last couple of months.
Milind Kotecha: "...the products that we are getting into ECH and CPVC they are high value products because of which we are at least visibly confident enough to reach to have a 50% growth on the current FY2023 so that reaches around 2250 of revenue."
Integration as Competitive Moat
- Not a standalone Chlor-Alkali play: The caustic soda expansion is built on internal consumption of chlorine and hydrogen into ECH and CPVC, making the model fundamentally different from standalone Chlor-Alkali players who face the challenge of chlorine disposal.
- Cost structure advantage: QoQ gross margin improvement is attributed to the strength of a completely integrated complex, where one product feeds into another value-added capacity, reducing manufacturing, transportation, sales, and distribution costs.
- Global supply context: Management argues caustic soda is in short supply globally and will not be oversupplied; the real challenge for Chlor-Alkali players is integration, and Epigral is "better off" because it is well integrated.
- Capacity absorption confidence: The entire increase in caustic soda capacity is expected to be absorbed, with utilization expected to remain above 89%; the optimum level on the existing 315 KTA capacity is 90%, and running at 90% is the optimum level.
Maulik Patel: "Caustic soda is never going to be issue in the world because right now it is short supply and people are doing the net export from the country like India, so again challenge with all the Chlor-Alkali player will be how they are integrated, how they will consume chlorine and hydrogen, I think you must have noticed that we are coming with epichlorohydrin and the chlorinated PVC plant, which will consume chlorine, which is coming out from our expansion of a caustic soda plant, so we are well integrated so we are better off we feel that in the coming times once we commission caustic soda along with both the derivatives together."
Balance Sheet & Capital Allocation
- Debt peak confirmed: Gross debt reached its highest level of ₹965 Cr in FY22; management stated this is the peak, with no additional borrowing planned for the chlorotoluene project, which will be funded through internal accruals.
- Debt reduction path: Approximately ₹140–150 Cr in annual repayments are scheduled; debt-to-EBITDA improved to 1.9x (1.5x excluding preference shares) and is guided to remain below 2x.
- Preference shares: ₹211 Cr of 8% preference shares were issued to Meghmani Organics with a 20-year redemption period; management is not expecting to redeem them in the near future, at least not in the next 2–3 years, though free cash flow after expansion projects could open the door to a rethink.
- Greenfield cost inflation: Management declined to give a precise Greenfield capex per ton for caustic soda, citing "crazy" current prices for steel, cement, and equipment, but noted it would be at least 50% higher than the past benchmark of ~₹40,000/ton; the new 110,000-ton expansion benefits from reusing majority infrastructure from the previous phase, keeping incremental capex very low.
- Future project pipeline: Many projects are under discussion to reach the ₹5,000 Cr target, focused on chemistries that are first-time-in-India, import substitutes, and chlorine or hydrogen derivatives; announcements will follow Board approval.
Sanjay Jain: "Our debt has increased to a highest level of 965 Crores in FY2022, but this is a peak level."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY23 revenue growth | 20–22% volume growth, 50% value growth (~₹2,250 Cr) | FY23 |
| ECH plant commissioning | Full-fledged commissioning, trial runs from May 15, 2022 | End of May / early June 2022 |
| CPVC plant commissioning | Commissioning | Early Q2 FY23 |
| ECH capacity ramp | ~40–50% utilization initially, gradual increase from Q3 onward | Q2 FY23 → Q3 FY23 |
| Long-term EBITDA margin | 28% ±2% (range 26–30%) | Long-term |
| Debt-to-EBITDA guardrail | Remain below 2x | Ongoing |
| Annual debt repayment | ~₹140–150 Cr per year | FY23 and beyond |
| Five-year revenue target | ₹5,000 Cr, 25% CAGR from FY22 base | By FY27 |
| Chlorotoluene project capex | ~₹180 Cr, funded through internal accruals | Spend split across FY23 and FY24 |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| Revenue | ₹499 cr, up 93% YoY |
| EBITDA | ₹175 cr, up 118% YoY |
| EBITDA margin | 35%, highest level |
| PAT | ₹99 cr, up 202% YoY |
| PAT margin | 20% |
| FY22 revenue | ₹1,551 cr, up 87% YoY |
| FY22 PAT | ₹253 cr, up 2.5x YoY |
| FY22 EBITDA margin | 33% |
| FY22 volume growth | 20% |
| FY23 value growth guidance | 50% |
| FY23 volume growth guidance | 20% |
| Five-year revenue target | ₹5,000 cr by FY27, CAGR 25% |
| Caustic soda ECU realization | ₹49,300, up from ₹45,800 in Q3 |
| Overall plant utilization | 87% in FY22, improved 6% vs FY21 |
| Hydrogen peroxide utilization | 78% in FY22 vs 57% in FY21 |
| Debt to EBITDA | 1.9x vs 2.1x in FY21 |
| Long-term debt | ₹965 cr peak in FY22 |
| Power cost per unit | ₹9.15 in Q4 vs ₹7.67 for full FY22 |
| Coal consumption cost | ~₹9,000 per metric ton in Q4 |
| Exports share | 5% of total products in FY22 |